BBIO

36.30

0.96% 0.345

Handel nachbörslich: 36.31 0.005 +0.01%

Bridgebio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Schlusskurs vom Vortag:

$35.96

Offen:

$35.2

24-Stunden-Volumen:

1.29M

Relative Volume:

0.47

Marktkapitalisierung:

$6.37B

Einnahmen:

$217.77M

Nettoeinkommen (Verlust:

$-438.86M

KGV:

-15.06

EPS:

-2.41

Netto-Cashflow:

$-456.33M

1W Leistung:

+7.19%

1M Leistung:

-1.18%

6M Leistung:

+52.29%

1J Leistung:

+49.22%

1-Tages-Spanne:

$35.13

$36.35

1-Wochen-Bereich:

$33.21

$36.35

52-Wochen-Spanne:

$21.62

$39.47

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Firmenname

Bridgebio Pharma Inc

Sektor

Healthcare (1154)

Branche

Biotechnology (677)

Telefon

(650) 391-9740

Adresse

3160 PORTER DR., PALO ALTO, CA

Mitarbeiter

730

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BBIO Bridgebio Pharma Inc	36.30	6.37B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-03	Eingeleitet	Oppenheimer	Perform
2024-09-04	Eingeleitet	Piper Sandler	Overweight
2024-03-21	Fortgesetzt	Raymond James	Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Market Perform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-07	Eingeleitet	Citigroup	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-07-18	Herabstufung	Jefferies	Buy → Hold
2023-04-19	Eingeleitet	Evercore ISI	Outperform
2023-02-06	Eingeleitet	Cowen	Outperform
2021-12-27	Bestätigt	Mizuho	Buy
2021-12-27	Bestätigt	SVB Leerink	Outperform
2021-09-10	Hochstufung	BofA Securities	Neutral → Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-03-22	Bestätigt	Goldman	Buy
2021-02-22	Fortgesetzt	JP Morgan	Overweight
2021-02-09	Fortgesetzt	Goldman	Buy
2021-01-11	Bestätigt	H.C. Wainwright	Buy
2020-12-10	Bestätigt	H.C. Wainwright	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Neutral
2020-05-19	Eingeleitet	BTIG Research	Buy
2020-04-13	Eingeleitet	H.C. Wainwright	Buy
2020-02-19	Eingeleitet	Mizuho	Buy
2019-07-26	Eingeleitet	Raymond James	Outperform
2019-07-22	Eingeleitet	BMO Capital Markets	Outperform
2019-07-22	Eingeleitet	Goldman	Buy
2019-07-22	Eingeleitet	JP Morgan	Overweight
2019-07-22	Eingeleitet	Jefferies	Buy
2019-07-22	Eingeleitet	Piper Jaffray	Overweight
2019-07-22	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

Apr 23, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO) - PrimePublishers.com

Apr 23, 2025

Apr 22, 2025

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events - ADVFN

Apr 22, 2025

BridgeBio: Early Signs Point To Blockbuster Revenues - Seeking Alpha

Apr 22, 2025

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET | BBIO Stock News - GuruFocus

Apr 22, 2025

BridgeBio Pharma, Inc. to Report First Quarter Financial Results and Program Updates on April 29, 2025 - Nasdaq

Apr 22, 2025

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET - TradingView

Apr 22, 2025

BridgeBio Sets Q1 2025 Earnings Call: Key Genetic Disease Pipeline Updates Expected April 29 - Stock Titan

Apr 22, 2025

Apr 16, 2025

BridgeBio Pharma director Ellis sells $350,000 in stock By Investing.com - Investing.com South Africa

Apr 16, 2025

BridgeBio Pharma director Ellis sells $350,000 in stock - Investing.com Australia

Apr 16, 2025

Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool

Apr 15, 2025

BridgeBio (BBIO) Receives Increased Price Target from H.C. Wainw - GuruFocus

Apr 15, 2025

Apr 12, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News - GuruFocus

Apr 12, 2025

BridgeBio Pharma (BBIO) Sees Promising Growth Amid Market Volati - GuruFocus

Apr 12, 2025

Apr 11, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025

BridgeBio Expands Team: Strategic Equity Grants Awarded to 20 New Hires - Stock Titan

Apr 11, 2025

Apr 10, 2025

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX) - The Globe and Mail

Apr 10, 2025

Apr 04, 2025

BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 03, 2025

BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com India

Apr 03, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq

Apr 03, 2025

Apr 01, 2025

Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada

Apr 01, 2025

Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan

Apr 01, 2025

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire

Apr 01, 2025

Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa

Mar 31, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq

Mar 31, 2025

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener

Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com

Mar 31, 2025

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - Yahoo Finance

Mar 31, 2025

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - MarketScreener

Mar 31, 2025

Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India

Mar 31, 2025

Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Mar 31, 2025

Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan

Mar 31, 2025

Mar 29, 2025

Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus

Mar 29, 2025

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025

(BBIO) Technical Data - news.stocktradersdaily.com

Mar 29, 2025

Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN

Mar 29, 2025

Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada

Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India

Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa

Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025

BridgeBio’s Beyonttra approved in Japan - The Pharma Letter

Mar 27, 2025

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com

Mar 27, 2025

BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq

Mar 27, 2025

Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - MarketScreener

Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra - Investing.com

Mar 27, 2025

Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan

Mar 27, 2025

Mar 24, 2025

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times

Mar 24, 2025

BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq

Mar 24, 2025

Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR

Mar 24, 2025

Mar 23, 2025

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN

Mar 23, 2025

Mar 22, 2025